Intra-Cellular Therapies starts trials in schizophrenia, opioid use disorder

 

• Intra-Cellular Therapies (NASDAQ:ITCI) has initiated clinical programs for its lumateperone long-acting injectable formulation (ITI-LLAI) and for ITI-333, a novel molecule for the treatment of opioid use disorder.
• LLAI, Study ITI-007-025: A Phase 1 study will evaluate the pharmacokinetics, safety and tolerability of lumateperone LAI in patients with stable symptoms of schizophrenia.
• Maintaining patients symptomatically stable and functional are the primary objectives of the treatment of schizophrenia.
• ITI-333, Study ITI-333-001: A Phase 1 study evaluating the safety, tolerability and pharmacokinetics of ITI-333 in healthy volunteers for the treatment of opioid use disorder and associated comorbidities (e.g., depression, anxiety, sleep disorders) without opioid-like safety and tolerability concerns.
• https://seekingalpha.com/news/3647694-intra-cellular-therapies-launches-clinical-trials-for-treatment-of-schizophrenia-and-opioid